Parkinson’s breakthrough: Researchers... - Parkinson's Movement

Parkinson's Movement

18,079 members18,278 posts

Parkinson’s breakthrough: Researchers find way to halt disease progression

JayPwP
JayPwP

Unable to find any further information...

mcknights.com/news/clinical...

19 Replies
oldestnewest

Unfortunately, the key words in the article are "in mice."

Those lucky mice!!

Xenos
Xenos in reply to jimcaster

I wonder if mice use humans for testing their drugs...

JayPwP
JayPwP in reply to Xenos

Good one

MarionP
MarionP in reply to Xenos

Douglas Adams thought so.

berti2206
berti2206 in reply to jimcaster

ça commence toujours ainsi et c'est très prometteur

jimcaster
jimcaster in reply to berti2206

Cela peut être encourageant, mais comme pour de nombreux autres essais sur souris réussis, je ne pense pas que je vivrai assez longtemps pour en bénéficier. J'espère que je me trompe.

berti2206
berti2206 in reply to jimcaster

mon épouse a 38 ans, a été diagnostiquée il y a 5 ans. J'éspère qu'elle bénéficiera des nouvelles technologies rapidement...

jimcaster
jimcaster in reply to berti2206

Être diagnostiqué à 33 ans a dû être difficile. J'espère et je crois qu'une percée majeure viendra bientôt.

JayPwP
JayPwP in reply to jimcaster

The post is hijacked :)

Will need Google translate

jimcaster
jimcaster in reply to JayPwP

Sorry. I used Google translate to reply to Berti2206 in French simply because he originally replied in French.

JayPwP
JayPwP in reply to jimcaster

No issues jim

here:

nature.com/articles/s41598-...

"For efficient knock down, we designed and synthesized an amido-bridged nucleic acids (AmNA)-modified antisense oligonucleotide (ASO) that targeted SNCA with improved stability and cellular uptake in vivo. AmNA-ASO efficiently downregulated SNCA at both the mRNA and protein level in vitro and in vivo. Notably, AmNA-ASO was efficiently delivered into the mouse brain by intracerebroventricular injection without the aid of additional chemicals. Furthermore, administration of AmNA-ASO ameliorated neurological defects in PD model mice expressing human wild type SNCA. Taken together, these findings suggest that AmNA-ASO is a promising therapeutic strategy for SNCA-associated pathology in PD."

Possibly helpful but it is a long way from an animal model that tries to replicate Parkinson's to approval for human use.

Bydureon, a repurposed Type 2 Diabetes drug is now in third-stage trials in UK for stopping Parkinson's in its tracks -- results expected 2023. Testing -- mice, open label, double blind -- has been going on for 10 years and it has been positive every time.

scienceofparkinsons.com/201...

Ten years. Geez what on earth could take that long.

JayPwP
JayPwP in reply to bubee

Missing intent

Xenos
Xenos in reply to bubee

Vaccines...

Crew

The study:

Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting α-synuclein as a novel therapy for Parkinson’s disease | 2020 pmc. Scientific Reports.

nature.com/articles/s41598-...

You may also like...